A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 May 2017
At a glance
- Drugs PD 325901 (Primary)
- Indications Neurofibromatoses; Plexiform neurofibroma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 19 Mar 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2018, according to ClinicalTrials.gov record.
- 19 Mar 2016 Planned primary completion date changed from 1 May 2016 to 1 Sep 2017, according to ClinicalTrials.gov record.